TNXP READ THE FULL TNXP RESEARCH REPORT Business Update No Advisory Committee Meeting for TNX-102 SL NDA On March 24, 2025, ...

Tonix Pharmaceuticals shares are trading higher by 22.5% during Monday's session. The company announced that the FDA will not ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a ...

FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 11.27%, which has investors questioning if this is right time to buy.

Tonix Pharmaceuticals (TNXP) announced the launch of TONIX ONE, a fully-integrated digital platform designed to help patients better understand ...

Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) plunged ~21% in the morning hours on Wednesday after the biotech fell short of Street forecasts with its Q4 2024 revenue ahead of a potential FDA nod for ...

The biotechnology sector has experienced a jolt of volatility over the past few days, spearheaded by the dramatic price ...

On March 24, Tonix Pharmaceuticals Holding announced that the FDA will not require an Advisory Committee meeting for its New ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...